Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase I clinical trial.

被引：0
|
作者：
Paul, R.
Holmes, J. P.
Amin, A.
Carmichael, M.
Jama, Y. H.
McNeill, A.
Hueman, M. T.
Craig, D.
Ponniah, S.
Peoples, G. E.
机构：
[1] Windber Med Ctr, Windber, PA USA
[2] Natl Naval Med Ctr, Bethesda, MD USA
[3] USUHS, Bethesda, MD USA
[4] Brooke Army Med Ctr, Ft Sam Houston, TX 78234 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S123 / S124
页数：2
相关论文
共 50 条
  • [1] Clinical and Immunologic Responses of HLA-A3+ Breast Cancer Patients Vaccinated with the HER2/neu-Derived Peptide Vaccine, E75, in a Phase I/II Clinical Trial
    Patil, Ritesh
    Clifton, Guy T.
    Holmes, Jarrod P.
    Amin, Asna
    Carmichael, Mark G.
    Gates, Jeremy D.
    Benavides, Linda H.
    Hueman, Matthew T.
    Ponniah, Sathibalan
    Peoples, George E.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (02) : 140 - 147
  • [2] Clinical and immunologic effects of a HER2/neu (E75) peptide vaccine booster in previously vaccinated breast cancer patients
    Holmes, J. P.
    Amin, A.
    Storrer, C. E.
    Smith, A. M.
    Jama, Y. H.
    McNeil, A.
    Craig, D.
    Ponniah, S.
    Peoples, G. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] The HLA-A2 restricted HER2/neu derived peptides (E75 and GP2) are both highly immunogenic in HLA-A3 breast cancer patients vaccinated with an E75 vaccine
    Clifton, Guy
    Patil, Ritesh
    Holmes, Jarrod
    Benavides, Linda
    Gates, Jeremy
    Jama, Yusuf
    Mursal, Mohamed
    Zacharia, Athina
    Ciano, Kathy
    Mittendorf, Elizabeth
    Ponniah, Sathibalan
    Peoples, George
    CANCER RESEARCH, 2009, 69
  • [4] The HLA-A2 restricted HER2/neu derived peptides (E75 and GP2) are both highly immunogenic in HLA-A3 breast cancer patients vaccinated with an E75 vaccine.
    Clifton, Guy
    Patil, Ritesh
    Holmes, Jarrod
    Benavides, Linda
    Gates, Jeremy
    Jama, Yusuf
    Mursal, Mohamed
    Zacharia, Athina
    Ciano, Kathy
    Mittendorf, Elizabeth
    Ponniah, Sathibalan
    Peoples, George
    CANCER RESEARCH, 2009, 69
  • [5] Pathologic and immunologic patterns among breast cancer (BCa) patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine (E75)
    Benavides, L. C.
    Gates, J. D.
    Arnin, A.
    Holmes, J. P.
    Carmichael, M. G.
    Hueman, M. T.
    Craig, D.
    Stojadinovic, A.
    Ponniah, S.
    Peoples, G. E.
    ANNALS OF SURGICAL ONCOLOGY, 2008, 15 : 76 - 76
  • [6] Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients
    Peoples, GE
    Gurney, JM
    Hueman, MT
    Woll, MW
    Ryan, GB
    Storrer, CE
    Fisher, C
    Shriver, CD
    Ioannides, CG
    Ponniah, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (30) : 7536 - 7545
  • [7] Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients.
    Gurney, JM
    Hueman, MT
    Woll, MM
    Ryan, GB
    Storrer, CE
    Fisher, C
    Shriver, CD
    Ioannides, CG
    Ponniah, S
    Peoples, GE
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 184S - 184S
  • [8] Clinical results of a phase I trial of a HER2/neu-derived peptide (GP2) vaccine in disease-free, node-negative breast cancer patients
    Carmichael, M.
    Holmes, J. P.
    Mittendorf, E. A.
    Amin, A.
    Hueman, M. T.
    Ponniah, S.
    Peoples, G. E.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S30 - S31
  • [9] Combined clinical trial results of a HER2/neu (E75) vaccine for prevention of recurrence in high-risk breast cancer patients.
    Peoples, G. E.
    Khoo, S.
    Dehqanzada, Z. A.
    Mittendorf, E. A.
    Hueman, M. T.
    Gurney, J. M.
    Woll, M. M.
    Ryan, G. B.
    Storrer, C. E.
    Harris, K. A.
    Jama, Y. H.
    Smith, A. M.
    Shriver, C. D.
    Ioannides, C. G.
    Ponniah, S.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S6 - S6
  • [10] Optimal dose and schedule of a HER2/neu peptide (E75) vaccine in disease-free breast cancer patients: results from two phase I/II clinical trials
    Holmes, J. P.
    Patil, R.
    Amin, A.
    Jama, Y. H.
    McNeill, A.
    Hueman, M. T.
    Craig, D.
    Ponniah, S.
    Peoples, G. E.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S30 - S30
12345